Arvinas Inc

ARVN is in an early Stage 1 consolidation following a terminal decline, with a Bullish Pivot Point pattern signaling failure of downside control and structural repair toward a higher equilibrium. The medium-term bias is bullish within this emerging base, but short-term conditions are extended near the upper boundary and RSI is overbought. Execution should be deferred, stalking for a pullback and absorption around the rising 9/20 EMA zone near prior resistance.

• ↑Q2 2026 revenue jumped to $249.7 M (+1,045% YoY) from $22.4 M a year ago
• ↑Diluted EPS of $2.58 in Q2 vs loss of $0.84 prior year marks profitability shift
• ↓Q2 profit relies on $112.5 M in Pfizer/Rigel licensing revenue with no guarantee of repeats